In Lucem

In Lucem” is Latin for “into the light”. In Lucem is a boutique consulting firm that guides pharmaceutical companies to capitalize on the burgeoning biosimilars market in Asia Pacific. The Asia Pacific biosimilars market is expected to grow from US$ 3,141.28 million in 2022 to US$ 22,533.11 million by 2028, at a CAGR of 38.9% from 2022 to 2028, according to Business Market Insights 1. Another report by Research and Markets suggests that the Asia Pacific biosimilars market will grow by 30.7% annually with a total addressable market cap of $140.4 billion over 2021-2030 owing to the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions 2. In Lucem provides tailored consulting services to guide your biosimilars journey in Asia Pacific. Our expertise encompasses business turnaround, market access, and market entry strategies aligned with your business goals. With the Asia Pacific region projected to become the largest biosimilars market globally by 2030, In Lucem can help you unlock the vast potential of Asia Pacific biosimilars as your trusted partner.